Considering the process of immune surveillance in cancer [11, 12], it is likely that JAK1 mutant tumors are still recognizable to cells of the innate immune system (natural killer cells) or that JAK1 wildtype tumors have encountered other mechanisms to evade immune-mediated killing. The gene discussed is JAK1; the disease is cancer.